Your browser doesn't support javascript.
loading
Does Valved Holding Chamber Improve Aerosol Lung Deposition with a Jet Nebulizer? A Randomized Crossover Study.
Alcoforado, Luciana; Paiva, Dulciane Nunes; Ari, Arzu; Barcelar, Jacqueline de Melo; Brandão, Simone Cristina Soares; Fink, James B; Dornelas de Andrade, Armele.
Afiliação
  • Alcoforado L; Department of Physical Therapy, Universidade Federal de Pernambuco, Recife 50710-560, PE, Brazil.
  • Paiva DN; Department of Physical Education and Health, Universidade de Santa Cruz do Sul, Santa Cruz do Sul 96815-010, RS, Brazil.
  • Ari A; Department of Respiratory Therapy, Texas State University, Austin, TX 73301, USA.
  • Barcelar JM; Department of Physical Therapy, Universidade Federal de Pernambuco, Recife 50710-560, PE, Brazil.
  • Brandão SCS; Medicine Nuclear Department, Universidade Federal de Pernambuco, Recife 50710-560, PE, Brazil.
  • Fink JB; Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, Chicago, IL 60007, USA.
  • Dornelas de Andrade A; Department of Physical Therapy, Universidade Federal de Pernambuco, Recife 50710-560, PE, Brazil.
Pharmaceutics ; 14(3)2022 Mar 04.
Article em En | MEDLINE | ID: mdl-35335942
Using valved holding chambers (VHC) during aerosol therapy has been reported to improve the inhaled dose with various aerosol devices, including vibrating mesh nebulizers. The aim of this study was to quantify the pulmonary deposition of a jet nebulizer (JN) with and without a VHC, and a mesh nebulizer (MN) with a VHC in a randomized cross-over trial with seven healthy consenting adults. Our hypothesis was that the use of a VHC would improve deposition with the JN. Diethylnitriaminopentacetic acid with technetium (DTPA-Tc99m), with the activity of 1 mC with 0.9% saline solution was nebulized. The radiolabeled aerosol was detected by 2D planar scintigraphy after administration. The pulmonary deposition was greater with a JN with a VHC (4.5%) than a JN alone (3.2%; p = 0.005. However, an MN with a VHC (30.0%) was six-fold greater than a JN or JN with a VHC (p < 0.001). The extrapulmonary deposition was higher in the JN group without a VHC than in the other two modalities (p < 0.001). Deposition in the device was greater with a JN + VHC than an MN+/VHC (p < 0.001). Lower residual drug at the end of the dose was detected with an MN than either JN configuration. The exhaled dose was greater with a JN alone than either an MN or JN with VHC (p < 0.001). In conclusion, the addition of the VHC did not substantially improve the efficiency of aerosol lung deposition over a JN alone.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Pharmaceutics Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Pharmaceutics Ano de publicação: 2022 Tipo de documento: Article